# Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD

> **NCT00403442** · PHASE1 · TERMINATED · sponsor: **Vitreous -Retina- Macula Consultants of New York** · enrollment: 10 (estimated)

## Conditions studied

- Macular Degeneration

## Interventions

- **DEVICE:** Verteporfin Therapy/ Drug: Bevacizumab

## Key facts

- **NCT ID:** NCT00403442
- **Lead sponsor:** Vitreous -Retina- Macula Consultants of New York
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-09
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2008-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00403442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00403442, "Bevacizumab in Combination With Verteporfin Reduced and Standard Fluence in the Treatment of Hemorrhaged Lesions in Neovascular AMD". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00403442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*